Health Technology Assessment (HTA) overview
Australian Government Health Technology Assessment Process
The Therapeutic Goods Administration(TGA), the Medical Services Advisory Committee (MSAC), the Pharmaceutical Benefits Advisory Committee (PBAC) and the Prostheses List Advisory Committee (PLAC), each perform health technology assessment (HTA) processes to provide advice to the Australian Government Department of Health.
Each entity has complex and inter-dependent relationships with discrete functions that respond to different policy needs.
Efficient and effective HTA processes are crucial to supporting sustainable management of subsidised health technologies. Consistent application of evidence across Australian Government HTA processes is an important element in ensuring stakeholder confidence in the HTA framework by creating certainty in how these processes are implemented and their achieved outcome.
Each HTA agency supports the Australian Government HTA framework through the following functions:
1. Assessment of the safety and efficacy of health technologies for market regulation to ensure that therapeutic goods are safe, perform as intended and are produced using appropriate quality controls before marketing approval is granted in Australia through the Australian Register of Therapeutic Goods (ARTG); and
2. Appraisal of the comparative safety, clinical and cost effectiveness of health technologies which informs decisions about:
- 1. Public funding of medical services (with or without a device), procedures and diagnostic technologies, pharmaceuticals and vaccines through the Medicare Benefits Schedule (MBS), the Pharmaceutical Benefits Scheme (PBS) and the National Immunisation Program (NIP) respectively;
2. Private health insurance reimbursement of prosthetic devices through the Prostheses List; and
3. Post market surveillance of these health care interventions to inform ongoing decisions about the marketing approval of therapeutic goods or the reimbursement of health technologies that prove not to be safe, cost effective or do not perform as intended.
- HTA Policy Framework
- Market Regulation - therapeutic Goods Administration
- HTA for Reimbursement
- HTA for reimbursement - How to apply
- Pharmaceutical Benefits Scheme and the National Immunisation Program
- Codependent and Hybrid Technologies
- Medicare Benefits Schedule
- Prostheses List
- National Immunisation Program
- National Blood Agreement
- Post Market Surveillance
Top of page
Page currency, Latest update: 18 July, 2019